BR112022018909A2 - Compostos à base de indazol e métodos de uso associados - Google Patents
Compostos à base de indazol e métodos de uso associadosInfo
- Publication number
- BR112022018909A2 BR112022018909A2 BR112022018909A BR112022018909A BR112022018909A2 BR 112022018909 A2 BR112022018909 A2 BR 112022018909A2 BR 112022018909 A BR112022018909 A BR 112022018909A BR 112022018909 A BR112022018909 A BR 112022018909A BR 112022018909 A2 BR112022018909 A2 BR 112022018909A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- target protein
- present disclosure
- indazole
- associated methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 abstract 3
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 102100032783 Protein cereblon Human genes 0.000 abstract 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
COMPOSTOS À BASE DE INDAZOL E MÉTODOS DE USO ASSOCIADOS. Compostos bifuncionais que encontram utilidade como moduladores de cinase 2 de repetição rica em leucina (LRRK2) são aqui descritos. Em particular, os compostos heterobifuncionais da presente divulgação contêm, em uma extremidade, uma fração que liga à ubiquitina ligase E3 cereblon e, na outra extremidade uma fração que liga a LRRK2, de modo que a proteína alvo seja colocada em proximidade da ubiquitina ligase para efetuar degradação (e inibição) da proteína alvo. Os compostos heterobifuncionais da presente divulgação exibem uma ampla gama de atividades farmacológicas associadas à degradação/inibição de proteína alvo. Doenças ou distúrbios que resultam de regulação aberrante da proteína alvo são tratados ou prevenidos com compostos e composições da presente divulgação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992952P | 2020-03-21 | 2020-03-21 | |
| PCT/US2021/023183 WO2021194879A1 (en) | 2020-03-21 | 2021-03-19 | Indazole based compounds and associated methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018909A2 true BR112022018909A2 (pt) | 2022-12-13 |
Family
ID=75539924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018909A BR112022018909A2 (pt) | 2020-03-21 | 2021-03-19 | Compostos à base de indazol e métodos de uso associados |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210315896A1 (pt) |
| EP (1) | EP4121422A1 (pt) |
| JP (1) | JP2023518830A (pt) |
| KR (1) | KR20230004511A (pt) |
| CN (1) | CN115697990A (pt) |
| AU (1) | AU2021244180A1 (pt) |
| BR (1) | BR112022018909A2 (pt) |
| CA (1) | CA3172387A1 (pt) |
| CO (1) | CO2022014718A2 (pt) |
| IL (1) | IL296648A (pt) |
| MX (1) | MX2022011674A (pt) |
| WO (1) | WO2021194879A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023018973A2 (pt) * | 2021-03-19 | 2023-12-12 | Arvinas Operations Inc | Compostos à base de indazol e métodos associados de uso |
| CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
| EP4276097A1 (en) | 2022-05-10 | 2023-11-15 | University Of Dundee | Aminopyrimidinyl derivatives for the treament of parkinson's disease |
| WO2024010818A2 (en) * | 2022-07-07 | 2024-01-11 | University Of Tennessee Research Foundation | Proteolysis targeting chimera (protac) of selective androgen receptor degrader (sard) compounds and methods of use thereof |
| WO2024054876A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Leucine rich repeat kinase 2 (lrrk2) degrading compounds and associated methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| CA2797947C (en) * | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
| KR102204989B1 (ko) | 2012-01-12 | 2021-01-20 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014134776A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134774A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EP3035800B1 (en) | 2013-08-22 | 2019-10-09 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| MX2016013563A (es) | 2014-04-14 | 2017-05-09 | Arvinas Inc | Moduladores de la proteolisis basados en imida y metodos de uso asociados. |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2018148443A1 (en) * | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation with heterobifunctional compounds |
| WO2020081682A1 (en) * | 2018-10-16 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
-
2021
- 2021-03-19 US US17/207,325 patent/US20210315896A1/en active Pending
- 2021-03-19 IL IL296648A patent/IL296648A/en unknown
- 2021-03-19 KR KR1020227036283A patent/KR20230004511A/ko unknown
- 2021-03-19 BR BR112022018909A patent/BR112022018909A2/pt not_active Application Discontinuation
- 2021-03-19 JP JP2022557169A patent/JP2023518830A/ja active Pending
- 2021-03-19 CN CN202180035521.9A patent/CN115697990A/zh active Pending
- 2021-03-19 CA CA3172387A patent/CA3172387A1/en active Pending
- 2021-03-19 AU AU2021244180A patent/AU2021244180A1/en active Pending
- 2021-03-19 EP EP21719336.6A patent/EP4121422A1/en active Pending
- 2021-03-19 MX MX2022011674A patent/MX2022011674A/es unknown
- 2021-03-19 WO PCT/US2021/023183 patent/WO2021194879A1/en active Application Filing
-
2022
- 2022-10-18 CO CONC2022/0014718A patent/CO2022014718A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3172387A1 (en) | 2021-09-30 |
| KR20230004511A (ko) | 2023-01-06 |
| MX2022011674A (es) | 2022-12-15 |
| EP4121422A1 (en) | 2023-01-25 |
| JP2023518830A (ja) | 2023-05-08 |
| CN115697990A (zh) | 2023-02-03 |
| US20210315896A1 (en) | 2021-10-14 |
| AU2021244180A1 (en) | 2022-11-03 |
| CO2022014718A2 (es) | 2022-10-31 |
| WO2021194879A1 (en) | 2021-09-30 |
| IL296648A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018909A2 (pt) | Compostos à base de indazol e métodos de uso associados | |
| BR112023021265A2 (pt) | Moduladores da proteólise de bcl6 e métodos de uso associados | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| BR112022020841A2 (pt) | Inibidores de kras tricíclicos fundidos | |
| CL2022000751A1 (es) | Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419) | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| BR112015027319A8 (pt) | Métodos e composições para modular a expressão de apolipoproteína (a) | |
| BR112022003184A2 (pt) | Inibidores de pirazolo[3,4-b]pirazina shp2 fosfatase | |
| BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
| BR112019024264A2 (pt) | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer | |
| BR112022020807A2 (pt) | Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3 | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| AR002267A1 (es) | Compuestos de imidazol utiles para el tratamiento de patologias mediadas por citoquinas; composicion farmaceutica que los contiene; proceso para preparar dichos compuestos; uso del mismo para preparar dichas composiciones; compuestos intermediarios y procesos para su preparacion. | |
| BR0208373A (pt) | Inibidores da tirosina cinase | |
| BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| AR124547A1 (es) | Degradadores de irak y sus usos | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| BR112021014406A2 (pt) | Derivados de tiazolopiridina como antagonistas de receptor de adenosina | |
| BR112022010054A2 (pt) | Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso | |
| MX2022011697A (es) | Inhibidores de ciclofilina y usos de los mismos. | |
| BR112022013478A2 (pt) | Compostos de esteroides alvejados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |